Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | 1.31% | |
| Lower Bollinger Band Walk | Weakness | 1.31% | |
| Inside Day | Range Contraction | 1.31% | |
| Wide Bands | Range Expansion | 1.31% | |
| Lower Bollinger Band Touch | Weakness | 1.31% | |
| Oversold Stochastic | Weakness | 1.31% |
| Alert | Time |
|---|---|
| Down 1% | 2 days ago |
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
| Rose Above Lower Bollinger Band | 3 days ago |
| Up 1% | 3 days ago |
Get a Trading Assistant
- Earnings date: 05/07/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Organic Chemistry Chronic Lymphocytic Leukemia Lymphocytic Leukemia Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.52 |
| 52 Week Low | 3.2101 |
| Average Volume | 156,517 |
| 200-Day Moving Average | 8.42 |
| 50-Day Moving Average | 4.54 |
| 20-Day Moving Average | 4.27 |
| 10-Day Moving Average | 3.92 |
| Average True Range | 0.36 |
| RSI (14) | 32.89 |
| ADX | 22.59 |
| +DI | 12.02 |
| -DI | 29.90 |
| Chandelier Exit (Long, 3 ATRs) | 3.91 |
| Chandelier Exit (Short, 3 ATRs) | 4.28 |
| Upper Bollinger Bands | 5.25 |
| Lower Bollinger Band | 3.28 |
| Percent B (%b) | 0.09 |
| BandWidth | 46.12 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.21 |
| MACD Histogram | -0.0982 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.86 | ||||
| Resistance 3 (R3) | 3.83 | 3.68 | 3.80 | ||
| Resistance 2 (R2) | 3.68 | 3.58 | 3.69 | 3.77 | |
| Resistance 1 (R1) | 3.57 | 3.52 | 3.63 | 3.60 | 3.75 |
| Pivot Point | 3.42 | 3.42 | 3.44 | 3.43 | 3.42 |
| Support 1 (S1) | 3.31 | 3.32 | 3.37 | 3.34 | 3.19 |
| Support 2 (S2) | 3.16 | 3.26 | 3.17 | 3.17 | |
| Support 3 (S3) | 3.05 | 3.16 | 3.15 | ||
| Support 4 (S4) | 3.08 |
